

PRODUCT INFORMATION

| | |
|---|---|
| Common Name | Bimzelx;CDP-4940;CDP4940;UCB-4940;UCB4940 |
| Conjugate | Biotinylated |
| Synonyms | IL17;CTLA8;IL-17;ILA17;CTLA-8;IL-17A |
| Applications | N/A |
| Endotoxin | Less than 1.0 EU/μg by the LAL method. For <1 EU/mg requirements, please contact us for customization. |
| Recommended Dilutions | N/A |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | N/A |
| IgG type | Human IgG1(E356D,M358L) - kappa |
| Reactivity | Human |
| Target | IL17A |
| Uniprot ID | Q16552 |
| Description | Biotinylated Anti-IL17A(bimekizumab biosimilar) mAb |
| Delivery | 6-8 weeks |
| Storage&Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Sterility | Products are supplied non-sterile. For cell culture applications, dilute in appropriate medium and sterile-filter (0.22 μm) prior to use. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |

